PER 0.00% 10.0¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-10

  1. 11,041 Posts.
    lightbulb Created with Sketch. 985
    Hahaha, a convincing argument kp.... if you choose to ignore the facts that is...
    So they invested a million dollars to make you guru?
    I'll cogitate on that kp, not that you don't bring serious thought to the table.....

    not in yet kp?
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.